Regeneron’s Eylea (aflibercept) Receives the US FDA’s Approval as a Prefilled Syringe

 Regeneron’s Eylea (aflibercept) Receives the US FDA’s Approval as a Prefilled Syringe

Regeneron’s Eylea (aflibercept) Injection Receives the US FDA’s Approval as a Prefilled Syringe

Shots:

  • The US FDA has approved the Chemistry, Manufacturing and Controls (CMC) Prior-Approval Supplement (PAS) for the Eylea (2mg, single dose) sterilized prefilled syringe with its expected availability to the physicians and patients in H2’19
  • The sterilized prefilled syringe offers the same medication as the currently available Eylea providing ease of administration and is available in multiple dosing intervals, offering doctors the flexibility to address patient’s needs
  • Eylea is a VEGF inhibitor targeting VEGF-A and PLGF, formulated as an injection for the eye, act by blocking the growth of new blood vessels and by decreasing vascular permeability in the eye and is approved therapy for Wet AMD, macular edema following RVO, DME and DR in the US  

Click here to­ read full press release/ article | Ref: Regeneron | Image: Wsca

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post